COMMUNIQUÉS West-GlobeNewswire

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
18/03/2026
TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, [...]
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
18/03/2026
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass [...]
WallabyPhenox Restructures Debt and Accelerates Global Growth
18/03/2026
IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- WallabyPhenox, a global neurovascular medical technology company, today announced the successful completion of a significant financing round aimed at strengthening its [...]
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
18/03/2026
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its [...]
Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative
18/03/2026
PacBio’s Revio system and SPRQ-Nx chemistry to enable an order-of-magnitude expansion of HiFi metagenomic sequencing for scaling AI-designed therapeutics MENLO PARK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- PacBio ( [...]
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
18/03/2026
Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasms Financing led by Point72 with participation from additional [...]
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
18/03/2026
- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing [...]
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
18/03/2026
Portfolio receipts : • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up 68% versus full [...]
Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership
18/03/2026
ORION CORPORATION PRESS RELEASE 18 March 2026 at 10:00 EET Peace through well-being: Orion and CMI - Martti Ahtisaari Peace Foundation announce partnership Orion Corporation (“Orion Pharma”) and CMI - Martti Ahtisaari [...]
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
18/03/2026
43% of pet owners report that their pets experienced parasite infections, with 75% looking for clearer parasite prevention advice. Veterinarians are seen as the most trusted source of pet health advice. “Small acts of [...]
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
18/03/2026
STAFFORD, Texas, March 18, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
18/03/2026
The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal onset seizures [...]
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
18/03/2026
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 18, 2026 (GLOBE NEWSWIRE) -- Significant clinical and regulatory progress across entire pipeline BV100: Initiated global registrational Phase 3 (RIV- [...]
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
18/03/2026
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s [...]
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
18/03/2026
Sanofi’s venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to [...]
UREVO Unveils CyberMega Across the DACH Region: The First Smart Treadmill Engineered for Marathon Training at Home
18/03/2026
BERLIN, March 18, 2026 (GLOBE NEWSWIRE) -- As marathon participation rises, runners increasingly require equipment that replicates the rigor and precision of road racing. To meet this demand, UREVO launched the [...]
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
18/03/2026
Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt [...]
Ipsen présente le potentiel transformateur de son pipeline d’immuno oncologie précoce au congrès AACR
18/03/2026
Les données précliniques d’IPN01203 seront dévoilées lors de la convoitée session « New Drugs on the Horizon », mettant en lumière le potentiel précoce de ce nouvel activateur de cellules T à transformer la prise en [...]
Valneva publie ses résultats financiers audités et consolidés pour l’exercice 2025
18/03/2026
Chiffre d’affaires de 174,7 millions d’euros, conforme aux prévisions, dont 157,9 millions de ventes de produits Solide position de trésorerie de 109,7 millions d’euros et flexibilité financière renforcée suite au [...]

Pages